Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study

Bone Marrow Transplantation

Volumn 49, Issue 5, 2014, Pages 691-698

  Bilmon, I A ^a   Ashton, L ^b   Le Marsney, R E ^b   Dodds, A J ^a   O'brien, T A ^c,o   Wilcox, L ^a,e   Nivison Smith, I ^a,e   Daniels, B ^b   Vajdic, C M ^b,f   Le Marsney, R ^d   Dodds, A ^a   Tan, J ^a   Bilmon, I ^a   Aarons, D ^e   Tran, S ^e   Gibson, J ^g   Johnston, A ^g   Greenwood, M ^h   Forbes, M ^h   Hertzberg, M ⁱ   Huang, G ⁱ   Spencer, A ^j   Muirhead, J ^j   Szer, J ^k   Mason, K ^k   Lewis, I ^l   To, C ^l   Durrant, S ^m   Western, R ⁿ   Cannell, P ^c   Buffery, S ^c   Oswald, C ^o   Nelson, A ^o   Shaw, P ^p   Pearson, L ^p   Tiedemann, K ^q   Scoyne, M ^q   Fraser, C ^r   Seljak, J ^r   Cole, C ^s   Rowland, K ^s   Gough, H ^s   Tapp, H ^d   Green, N ^d   Moa, A ^k   McRae, J ^k   Jenkins, M ^k   Hicks, J ^l   Chaplin, K ^l   more..

^a ST VINCENT S HOSPITAL   (Australia)

^b University of New South Wales Sydney   (Australia)

^c SYDNEY CHILDREN'S HOSPITAL   (Australia)

^d CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^e ABMTRR   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

^j ALFRED HOSPITAL   (Australia)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l ROYAL ADELAIDE HOSPITAL   (Australia)

^m ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁿ ROYAL PERTH HOSPITAL   (Australia)

^o CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^p ROYAL CHILDREN'S HOSPITAL   (Australia)

^q ROYAL CHILDREN'S HOSPITAL   (Australia)

^r PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^s WOMEN S AND CHILDREN S HOSPITAL   (Australia)

more..

Author keywords

autologous transplantation; outcomes; risk; surveillance

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; AUSTRALIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVOR; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GRAFT RECIPIENT; HUMAN; LUNG CANCER; MALE; MELANOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; TESTIS CANCER; AUTOTRANSPLANTATION; EPIDEMIOLOGY; HEALTH SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; REGISTER; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; POPULATION SURVEILLANCE; REGISTRIES; RISK FACTORS; SKIN NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84922062629     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.13     Document Type: Article

References (40)

1. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DDF, Moore JJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Trans 2007; 13: 905-912
2. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Hematopoietic stem cell transplantation. JAMA 2010; 303: 1617-1624
3. Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011-1016
4. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784-789
5. Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187-2192
6. Bhatia S, Ramsay N, Steinbuch M, Dusenbery K, Shapiro R, Weisdorf D et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639
7. Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471
8. Baker KS, DeFor TE, Burns LJ, Ramsay NKC, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358
9. Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183
10. Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study. Blood 2003; 101: 2015-2023
11. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 2208-2214
12. Forrest DL, Nevill TJ, Naiman SC, Le A, Brockington DA, Barnett MJ et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: Incidence and risk factor analysis. Bone Marrow Transplant 2003; 32: 915-923
13. Cohen A, Rovelli A, Merlo DF, Van Lint MT, Lanino E, Bresters D et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: An EBMT Late Effects Working Party study. J Clin Oncol 2007; 25: 2449-2454
14. Seshadri T, Pintilie M, Kuruvilla J, Keating A, Tsang R, Zadeh S et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 380-386
15. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: A 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011; 29: 814-824
16. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Szer J. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: Progress report from the Australasian Bone Marrow Transplant Recipient Registry. Int Med J 2005; 35: 18-27
17. Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K et al. Solid tumors after hematopoietic stem cell transplantation in Japan: Incidence, risk factors and prognosis. Bone Marrow Transplant 2005; 36: 115-121
18. Krishnan AY, Mei M, Sun C-L, Thomas SH, Teh JB, Kang T et al. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Trans 2012; 19: 260-265
19. Fenk R, Neubauer F, Bruns I, Schröder T, Germing U, Haas R et al. Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Br J Haem 2012; 156: 683-686
20. Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant 2013; 48: 363-368
21. Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H et al. Second cancers among 40 576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005; 97: 1354-1365
22. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386-3391
23. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study. Haematologica 2008; 93: 398-404
24. Lens MB, Newton-Bishop JA. An association between cutaneous melanoma and non-Hodgkin's lymphoma: Pooled analysis of published data with a review. Ann Oncol 2005; 16: 460-465
25. Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926-4933
26. Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-Analysis. Lancet 2007; 370: 59-67
27. Vajdic CM, Van Leeuwen MT, Webster AC, McCredie MRE, Stewart JH, Chapman JR et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 2009; 18: 2297-2303
28. Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin 2012; 30: 355-361
29. Hughes BR, Cunliffe WJ, Bailey CC. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ 1989; 299: 88-91
30. McGregor JM, JNWN Barker, Macdonald DM. The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol 1991; 16: 131-132
31. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95: 3273-3279
32. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: A search for common mechanisms. Br J Cancer 2001; 85: 997-1005
33. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK et al. New malignancies among cancer survivors. In: SEER Cancer Registries, 1973-2000. National Cancer Institute: Bethesda, MD, USA, 2006
34. Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011; 118: 4086-4092
35. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791
36. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781
37. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: A systematic review. Lancet Oncol 2005; 6: 773-779
38. Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers MED, Tichelli A et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: A report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008; 111: 939-944
39. Bishop MM, Lee SJ, Beaumont JL, Andrykowski MA, Rizzo JD, Sobocinski KA et al. The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. Biol Blood Marrow Trans 2010; 16: 207-214
40. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Trans 2012; 18: 348-371.